Host apolipoprotein b messenger RNA-editing enzyme catalytic polypeptide-like 3G is an innate defensive factor and drug target against hepatitis C virus

Hepatology

Volumn 53, Issue 4, 2011, Pages 1080-1089

  Peng, Zong Gen ^a   Zhao, Zhi Yun ^a   Li, Yan Ping ^a   Wang, Yu Ping ^a   Hao, Lan Hu ^a   Fan, Bo ^a   Li, Yu Huan ^a   Wang, Yue Ming ^a   Shan, Yong Qiang ^a   Han, Yan Xing ^a   Zhu, Yan Ping ^a   Li, Jian Rui ^a   You, Xue Fu ^a   Li, Zhuo Rong ^a   Jiang, Jian Dong ^a  

^a INSTITUTE OF MEDICINAL BIOTECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

[3 (ALPHA BROMOPROPYL)AMINO 4 METHOXY BENZENE] FORMYL(3',4',5' TRIMETHOXYBENZENE)AMIDE; ANTIVIRUS AGENT; APOLIPOPROTEIN B; APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE LIKE 3G; BILN 206; CILUPREVIR; HOST CELL FACTOR C1; IMB 26; INNATE DEFENSIVE FACTOR; MESSENGER RNA; N,N' (DIMETHYLBIPHENY1 4 4' DIYL)DIBENZENESULFONAMIDE; PLASMID DNA; RECOMBINANT ALPHA2B INTERFERON; RN 5; UNCLASSIFIED DRUG; VIRION INFECTIVITY FACTOR; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG TARGETING; ENZYME DEGRADATION; FEMALE; GENE MUTATION; GENE SILENCING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INNATE IMMUNITY; MALE; MIXED INFECTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA EDITING; VIRION; VIRUS GENOME; VIRUS IMMUNITY; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANISOLES; BENZAMIDES; CELL LINE; CYTIDINE DEAMINASE; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNITY, INNATE; MICE; RNA EDITING; VIRUS REPLICATION;

EID: 79953766387     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.24160     Document Type: Article

References (40)

1. Jarmuz A, Chester A, Bayliss J, Gisbourne J, Dunham I, Scott J, et al. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002; 79: 285-296.
2. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003; 300: 1112.
3. Guo F, Cen S, Niu M, Saadatmand J, Kleiman L. Inhibition of formula-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication. J Virol 2006; 80: 11710-11722.
4. Bishop KN, Verma M, Kim EY, Wolinsky SM, Malim MH. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathog 2008; 4:e1000231.
5. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, et al. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003; 302: 1056-1060.
6. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. J Virol 2003; 77: 11398-11407.
7. Nathans R, Cao H, Sharova N, Ali A, Sharkey M, Stranska R, et al. Small-molecule inhibition of HIV-1 Vif. Nat Biotechnol 2008; 26: 1187-1192.
8. Cen S, Peng ZG, Li XY, Li ZR, Ma J, Wang YM, et al. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J Biol Chem 2010; 285: 16546-16552.
9. Sasada A, Takaori-Kondo A, Shirakawa K, Kobayashi M, Abudu A, Hishizawa M, et al. APOBEC3G targets human T-cell leukemia virus type 1. Retrovirology 2005; 2: 32.
10. Köck J, Blum HE. Hypermutation of hepatitis B virus genomes by APOBEC3G, APOBEC3C and APOBEC3H. J Gen Virol 2008; 89: 1184-1191.
11. Narvaiza I, Linfesty DC, Greener BN, Hakata Y, Pintel DJ, Logue E, et al. Deaminase-independent inhibition of parvoviruses by the APOBEC3A cytidine deaminase. PLoS Pathog 2009; 5: e1000439.
12. Peng ZG, Fan B, Du NN, Wang YP, Gao LM, Li YH, et al. Small molecular compounds that inhibit hepatitis C virus replication through destabilizing heat shock cognate 70 messenger RNA. HEPATOLOGY 2010; 52: 845-853.
13. Lohmann V, Körner F, Koch J, Herian U, Theilmann L, Bartenschlager R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999; 285: 110-113.
14. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med 2005; 11: 791-796.
15. Yang JH, Lai JP, Douglas SD, Metzger D, Zhu XH, Ho WZ. Real-time RT-PCR for quantitation of hepatitis C virus RNA. J Virol Methods 2002; 102: 119-128.
16. Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L. The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem 2004; 279: 33177-33184.
17. Harris RS. Enhancing immunity to HIV through APOBEC. Nat Biotechnol 2008; 26: 1089-1090.
18. Zennou V, Bieniasz PD. Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. Virology 2006; 349: 31-40.
19. Sheehy AM, Gaddis NC, Choi JD, Malim MH. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002; 418: 646-650.
20. von Schwedler U, Song J, Aiken C, Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. J Virol 1993; 67: 4945-4955.
21. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356: 1445-1454.
22. Suspène R, Henry M, Guillot S, Wain-Hobson S, Vartanian JP. Recovery of APOBEC3-edited human immunodeficiency virus G->A hypermutants by differential DNA denaturation PCR. J Gen Virol 2005; 86: 125-129.
23. Holmes RK, Malim MH, Bishop KN. APOBEC-mediated viral restriction: not simply editing? Trends Biochem Sci 2007; 32: 118-128.
24. Bishop KN, Holmes RK, Malim MH. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. J Virol 2006; 80: 8450-8458.
25. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, et al. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Curr Biol 2005; 15: 166-170.
26. Nguyen DH, Gummuluru S, Hu J. Deamination-independent inhibition of hepatitis B virus reverse transcription by APOBEC3G. J Virol 2007; 81: 4465-4472.
27. Pauli EK, Schmolke M, Hofmann H, Ehrhardt C, Flory E, Münk C, et al. High level expression of the anti-retroviral protein APOBEC3G is induced by influenza A virus but does not confer antiviral activity. Retrovirology 2009; 6: 38.
28. Strebel K. APOBEC3G & HTLV-1: inhibition without deamination. Retrovirology 2005; 2: 37.
29. Irena Melnikova. Hepatitis C therapies. Nat Rev Drug Discov 2008; 7: 799-800.
30. Zeuzem S. Interferon-based therapy for chronic hepatitis C: current and future perspectives. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 610-622.
31. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009; 361: 580-593.
32. Mederacke I, Wedemeyer H, Manns MP. Boceprevir, an NS3 serine protease inhibitor of hepatitis C virus, for the treatment of HCV infection. Curr Opin Investig Drugs 2009; 10: 181-189.
33. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009; 360: 1839-1850.
34. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009; 360: 1827-1838.
35. Thompson AJ, McHutchison JG. Antiviral resistance and specifically targeted therapy for HCV (STAT-C). J Viral Hepat 2009; 16: 377-387.
36. Qiu P, Sanfiorenzo V, Curry S, Guo Z, Liu S, Skelton A, et al. Identification of HCV protease inhibitor resistance mutations by selection pressure-based method. Nucleic Acids Res 2009; 37: e74.
37. Susser S, Welsch C, Wang Y, Zettler M, Domingues FS, Karey U, et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. HEPATOLOGY 2009; 50: 1709-1718.
38. Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young SK, et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. HEPATOLOGY 2008; 48: 1769-1778.
39. Komohara Y, Yano H, Shichijo S, Shimotohno K, Itoh K, Yamada A. High expression of APOBEC3G in patients infected with hepatitis C virus. J Mol Histol 2006; 37: 327-332.
40. Vartanian JP, Henry M, Marchio A, Suspène R, Aynaud MM, Guétard D, et al. Massive APOBEC3 editing of hepatitis B viral DNA in cirrhosis. PLoS Pathog 2010; 6: e1000928.